AI assistant
Medistim — Earnings Release 2017
Feb 15, 2018
3662_rns_2018-02-15_e907b5fd-0615-461d-9416-ea1015beb725.html
Earnings Release
Open in viewerOpens in your device viewer
Results for the 4th quarter and preliminary results for 2017
Results for the 4th quarter and preliminary results for 2017
Medistim had record sales for a quarter and year. Sales for the quarter ended at MNOK 82.2 (MNOK 67.4), a 21.9 % growth. Sales for 2017 ended at MNOK 301.5 (MNOK 268.1), a growth of 12.5 %. Currency neutral sales of own products increased with 31.3 % for the quarter. For 2017, currency neutral growth in sales of own products was 15.7%. EBIT for the quarter ended at MNOK 16.4 (MNOK 9.7), a 67.9 % growth. For 2017 EBIT ended at MNOK 65.5 (MNOK 56.4) a 16.2 % growth. Sales in USA continues the solid growth and currency neutral sales growth was 27.8 % for the quarter and 16.9 % for the year. The probe production capacity has improved and previous issues are solved. Entered into a collaboration to develop new production technology partly financed by Norwegian Research Council. The Board suggests a dividend of NOK 2.00 per share (NOK 1.75).